A 65-year-old man was diagnosed with high-risk localized prostate cancer. The treatment plan consisted of prostate radiotherapy and hormone suppression with a LHRH agonist (goserelin 10.8 mg subcutaneously every three months) for 36 months. The only medication the patient had received previously was losartan for hypertension. Seventy-two hours after the first goserelin dose, he presented with skin lesions characterized by erythematous-infiltrative plaques on his face, elbows, upper torso, and forearms ( Fig. 1) . The patient had never noticed any type of skin lesion previously. He was then referred to Dermatology and slit-skin smears microscopy was performed, but no AcidFast Bacilli (AFB) were found. Further workup led to a skin biopsy that revealed the presence of Mycobaterium leprae whose features were consistent with Borderline-borderline leprosy with reversal (Leprosy type 1) reaction with a few AFB seen (Fig. 2) . He was treated with multibacillary polychemotherapy (Rifampin, dapsone and clofazimine).
Although the use of goserelin was considered a possible trigger for leprosy reaction, the medical team did not interrupt the hormone blockade. Soon after the patient received the second goserelin dose, the skin lesions became more erythematous, and he also presented with peripheral neuropathy (acute neuritis) on his right elbow and feet, which could lead to permanent nerve damage. Therefore, he was treated with prednisone 0.5 mg/kg and the lesions resolved. After four 
